ALSO NOTED: Merck cleared to sell Isentress in Canada; Sanofi, Astellas restructure Japanese venture;

> Merck's new, first-in-class HIV treatment Isentress won approval from Canadian regulators for patients resistant to other AIDS drugs. Report

> Sanofi-Aventis and Astellas Pharma say they're restructuring their joint venture by splitting up the rights to market various drugs. Report

> Teva Pharmaceutical Industries got the FDA's tentative nod to market a generic version of GlaxoSmithKline's Parkinson's drug Requip when its patent expires in May. Report

> Walgreen's has stopped filling prescriptions for four CVS Caremark drug plans, saying the reimbursement levels are too low. Report

> Lifecycle Pharma has tapped Hans Christian Teisen as its new chief financial officer; Teisen most recently served as CFO of the drug maker Bavarian Nordic. Report

> A Friedman Billings Ramsey analyst downgraded MGI Pharma's stock, joining market watchers skeptical that the up-for-sale biotech will attract suitors anytime soon. Report

> Questcor Pharmaceuticals upgraded its interim president Don M. Bailey to permanent president and chief executive. Report

> Canada's Axcan Pharma is being bought out for $1.3 billion by the private equity group TPG Capital. Report

> Regeneron is feeling the warm embrace of Sanofi-Aventis, France's acquisition-hungry pharma giant. Sanofi has upped its stake in Regeneron from 4 percent to 19 percent while putting up $85 million in an up-front fee to seal a development deal covering therapeutic antibodies. Report

> The latest survey from the National Venture Capital Association shows that biotechnology is still on a roll with investors. Report

And Finally... What's good for the gander isn't for the goose: A genetic variation puts women at risk of depression from chronic stress, but protects stressed-out men from the same mood disorder. Report

Suggested Articles

With AbbVie's two most recent launches outperforming expectations, investors could be looking at a steal with an Allergan merger looming.

Investors are clamoring for a CVR created in the BMS-Celgene deal, but it will only pay off if the FDA approves three hot pipeline projects.

Muzammil Mansuri, Sanofi’s EVP of strategy and business development since February 2016, is retiring at the end of November.